Cabaletta Bio, Inc. (CABA) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. At this time, I would like to welcome everyone to Caballero Bio's conference call and webcast. Currently, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. Please note that this call is being recorded and is the property of Caballero Bio. Unauthorized recording, reproduction, or transmission of this call without the express written consent of Caballero Bio is strictly prohibited. I would now like to turn the call over to Will Gramick, of precision aq please go ahead thank you michelle good morning everyone and thank you for joining cabaletta bios conference call and webcast to discuss clinical and translational data from the first eight patients in the phase one two reset program in myositis lupus and systemic sclerosis that were presented at acr convergence 2024 in oral and poster presentations over the weekend Before we begin, I encourage everyone to go to the Investors section of our website at cabalettabaya.com, where you can find the press release and slides related to today's call. I would like to remind everyone that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and your actual results may differ materially. Please review the risk factors in our SEC filings for additional details. We will begin the call with prepared remarks by Stephen Knicksberger, our CEO, Carl June, the director of the Center for Cellular Immunotherapies at Penn Medicine, pioneer of the first CAR-T cell therapy approved in oncology, and member of CAB11's Scientific Advisory Board, will provide an overview of the lessons from CAR-T cell therapy in oncology. as it relates to the expansion int...